Berninger Markus T, Wexel Gabriele, Rummeny Ernst J, Imhoff Andreas B, Anton Martina, Henning Tobias D, Vogt Stephan
Department of Orthopaedic Sports Medicine, Klinikum rechts der Isar der Technischen Universität München.
J Vis Exp. 2013 May 21(75):e4423. doi: 10.3791/4423.
The treatment of osteochondral articular defects has been challenging physicians for many years. The better understanding of interactions of articular cartilage and subchondral bone in recent years led to increased attention to restoration of the entire osteochondral unit. In comparison to chondral lesions the regeneration of osteochondral defects is much more complex and a far greater surgical and therapeutic challenge. The damaged tissue does not only include the superficial cartilage layer but also the subchondral bone. For deep, osteochondral damage, as it occurs for example with osteochondrosis dissecans, the full thickness of the defect needs to be replaced to restore the joint surface (1). Eligible therapeutic procedures have to consider these two different tissues with their different intrinsic healing potential (2). In the last decades, several surgical treatment options have emerged and have already been clinically established (3-6). Autologous or allogeneic osteochondral transplants consist of articular cartilage and subchondral bone and allow the replacement of the entire osteochondral unit. The defects are filled with cylindrical osteochondral grafts that aim to provide a congruent hyaline cartilage covered surface (3,7,8). Disadvantages are the limited amount of available grafts, donor site morbidity (for autologous transplants) and the incongruence of the surface; thereby the application of this method is especially limited for large defects. New approaches in the field of tissue engineering opened up promising possibilities for regenerative osteochondral therapy. The implantation of autologous chondrocytes marked the first cell based biological approach for the treatment of full-thickness cartilage lesions and is now worldwide established with good clinical results even 10 to 20 years after implantation (9,10). However, to date, this technique is not suitable for the treatment of all types of lesions such as deep defects involving the subchondral bone (11). The sandwich-technique combines bone grafting with current approaches in Tissue Engineering (5,6). This combination seems to be able to overcome the limitations seen in osteochondral grafts alone. After autologous bone grafting to the subchondral defect area, a membrane seeded with autologous chondrocytes is sutured above and facilitates to match the topology of the graft with the injured site. Of course, the previous bone reconstruction needs additional surgical time and often even an additional surgery. Moreover, to date, long-term data is missing (12). Tissue Engineering without additional bone grafting aims to restore the complex structure and properties of native articular cartilage by chondrogenic and osteogenic potential of the transplanted cells. However, again, it is usually only the cartilage tissue that is more or less regenerated. Additional osteochondral damage needs a specific further treatment. In order to achieve a regeneration of the multilayered structure of osteochondral defects, three-dimensional tissue engineered products seeded with autologous/allogeneic cells might provide a good regeneration capacity (11). Beside autologous chondrocytes, mesenchymal stem cells (MSC) seem to be an attractive alternative for the development of a full-thickness cartilage tissue. In numerous preclinical in vitro and in vivo studies, mesenchymal stem cells have displayed excellent tissue regeneration potential (13,14). The important advantage of mesenchymal stem cells especially for the treatment of osteochondral defects is that they have the capacity to differentiate in osteocytes as well as chondrocytes. Therefore, they potentially allow a multilayered regeneration of the defect. In recent years, several scaffolds with osteochondral regenerative potential have therefore been developed and evaluated with promising preliminary results (1,15-18). Furthermore, fibrin glue as a cell carrier became one of the preferred techniques in experimental cartilage repair and has already successfully been used in several animal studies (19-21) and even first human trials (22). The following protocol will demonstrate an experimental technique for isolating mesenchymal stem cells from a rabbit's bone marrow, for subsequent proliferation in cell culture and for preparing a standardized in vitro-model for fibrin-cell-clots. Finally, a technique for the implantation of pre-established fibrin-cell-clots into artificial osteochondral defects of the rabbit's knee joint will be described.
多年来,治疗骨软骨关节缺损一直是医生面临的挑战。近年来,对关节软骨和软骨下骨相互作用的深入了解使得人们更加关注整个骨软骨单元的修复。与软骨损伤相比,骨软骨缺损的再生要复杂得多,在手术和治疗方面面临的挑战也大得多。受损组织不仅包括表层软骨层,还包括软骨下骨。对于深度骨软骨损伤,例如剥脱性骨软骨炎所导致的损伤,需要替换缺损的全层组织以恢复关节表面(1)。合适的治疗方法必须考虑这两种具有不同内在愈合潜力的不同组织(2)。在过去几十年中,出现了几种手术治疗选择并已在临床上确立(3 - 6)。自体或异体骨软骨移植由关节软骨和软骨下骨组成,能够替换整个骨软骨单元。缺损处用圆柱形骨软骨移植物填充,旨在提供一个表面覆盖有透明软骨且形状一致的结构(3,7,8)。缺点是可用移植物数量有限、供体部位发病风险(自体移植时)以及表面不匹配;因此,这种方法的应用尤其限于大的缺损。组织工程领域的新方法为再生性骨软骨治疗开辟了有前景的可能性。自体软骨细胞植入标志着第一种基于细胞的治疗全层软骨损伤的生物学方法,目前在全球范围内已确立,即使在植入后10至20年也有良好的临床效果(9,10)。然而,迄今为止,该技术并不适用于治疗所有类型的损伤,如涉及软骨下骨的深度缺损(11)。三明治技术将骨移植与当前组织工程方法相结合(5,6)。这种结合似乎能够克服单独使用骨软骨移植所存在的局限性。在将自体骨移植到软骨下缺损区域后,在上方缝合接种有自体软骨细胞的膜,有助于使移植物的拓扑结构与损伤部位相匹配。当然,先前的骨重建需要额外的手术时间,而且常常甚至需要进行额外的手术。此外,迄今为止,缺乏长期数据(12)。不进行额外骨移植的组织工程旨在通过移植细胞的软骨生成和成骨潜力来恢复天然关节软骨的复杂结构和特性。然而,同样,通常或多或少只能再生软骨组织。额外的骨软骨损伤需要特定的进一步治疗。为了实现骨软骨缺损多层结构的再生,接种自体/异体细胞的三维组织工程产品可能具有良好的再生能力(11)。除了自体软骨细胞外,间充质干细胞(MSC)似乎是用于生成全层软骨组织的有吸引力的替代选择。在众多临床前体外和体内研究中,间充质干细胞已显示出优异的组织再生潜力(13,14)。间充质干细胞对于治疗骨软骨缺损的重要优势在于它们具有分化为骨细胞和软骨细胞的能力。因此,它们有可能使缺损实现多层再生。近年来,已经开发并评估了几种具有骨软骨再生潜力的支架,初步结果很有前景(1,15 - 18)。此外,纤维蛋白胶作为细胞载体已成为实验性软骨修复中的首选技术之一,并已成功应用于多项动物研究(19 - 21),甚至首次应用于人体试验(22)。以下方案将展示一种从兔骨髓中分离间充质干细胞、随后在细胞培养中增殖并制备用于纤维蛋白 - 细胞凝块的标准化体外模型的实验技术。最后,将描述一种将预先制备的纤维蛋白 - 细胞凝块植入兔膝关节人工骨软骨缺损的技术。